Cargando…
Chromogranin A as a valid marker in oncology: Clinical application or false hopes?
Chromogranin A, due to its primary expression throughout the neuroendocrine system, is a widely accepted biomarker for the assessment of neuro-endocrine tumors. It has been traditionally used in the management of patients with tumors of gastro-enteropancreatic origin. Lately, it has also been implic...
Autores principales: | Gkolfinopoulos, Stavros, Tsapakidis, Konstantinos, Papadimitriou, Konstantinos, Papamichael, Demetris, Kountourakis, Panteleimon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366937/ https://www.ncbi.nlm.nih.gov/pubmed/28396845 http://dx.doi.org/10.5662/wjm.v7.i1.9 |
Ejemplares similares
-
Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients’ decision making?
por: Gkolfinopoulos, Stavros, et al.
Publicado: (2018) -
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward
por: Papadimitriou, Konstantinos, et al.
Publicado: (2015) -
Outcomes of 556 consecutive patients with stage I-III colon cancer managed in a single center over 10 years
por: Xenophontos, Eleni, et al.
Publicado: (2021) -
Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018) -
Leptomeningeal metastases originated from esophagogastric junction/gastric cancer: A brief report of two cases
por: Kountourakis, Panteleimon, et al.
Publicado: (2018)